J&J raises guidance for 2026 on strong start to the year

Johnson & Johnson raised 2026 guidance after a strong start to the year, with sales of medications including Darzalex and Tremfya up 11% in the first three months of 2026. The company said its immunology franchise is performing well as it prepares to market a new psoriasis pill and benefits from stronger-than-expected results from another drug. J&J also continues to streamline the business, including plans to spin off its medical-devices unit after divesting Kenvue.

Analysis

The market is underestimating how much of J&J’s rerating can come from portfolio simplification rather than near-term revenue growth. A cleaner business mix lowers the conglomerate discount, but the bigger second-order effect is capital allocation: once the device separation becomes credible, management can push harder on buybacks and bolt-on pipeline M&A, which should support EPS multiple expansion over the next 6-18 months. That makes this less of a one-quarter earnings story and more of a structural quality-of-earnings trade.

The key competitive implication is that J&J’s immunology momentum increases pressure on other large-cap pharma names with exposed inflammation franchises. If the psoriasis launch lands well, the read-through is not just share gain in a niche category; it raises confidence in J&J’s broader ability to defend specialty pricing and convert R&D into launch-led growth, which could force peers to spend more on promotion and lifecycle management. That tends to compress returns on incremental R&D for competitors over the next several quarters.

The main risk is that the market is extrapolating too much from one strong quarter and one upcoming launch. Pharma optimism can reverse quickly if payer access is narrower than expected, if the psoriasis asset cannibalizes lower-margin legacy products, or if device separation execution introduces one-time charges and distraction. On the timing side, the next catalyst window is 1-3 months for guidance credibility and 6-12 months for evidence that the new product cycle is durable; the trade breaks if launches disappoint or if the spin-off narrative stalls.

The contrarian view is that the move may still be underappreciated because investors often treat large pharma as low-beta defensive income rather than a self-help transformation story. If the market re-rates J&J from stability multiple toward a higher-quality medtech/pharma hybrid with better growth visibility, the upside comes from multiple expansion more than earnings revisions. That favors owning J&J into catalysts rather than waiting for perfect fundamental confirmation.

Key Decisions for Investors

• Long JNJ vs. a basket of large-cap pharma laggards over 3-6 months; target 8-12% relative upside if the market rewards portfolio simplification and launch optionality.
• Buy JNJ on pullbacks around guidance-related consolidation; use a 3-6 month horizon and risk 5-7% downside to capture multiple expansion ahead of the device separation.
• Consider call spreads on JNJ for the next 6-9 months to express upside from spin-off optionality with defined premium risk; best if implied vol stays contained.
• Avoid chasing KVUE strength as a structural long; treat it as a funding source/relative-value short if consumer-health takeover enthusiasm decays post-close.
• Pair long JNJ / short a higher-exposure immunology peer if valuation diverges further; the thesis is that JNJ’s cleaner capital structure and launch cadence should command a premium over the next two quarters.